Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Fabry disease …
- Updated 05.24.2024
- Released 07.05.1994
- Expires For CME 05.24.2027
Fabry disease
Introduction
Overview
Fabry disease is an X-linked disorder of glycosphingolipid metabolism caused by a deficiency of alpha-galactosidase A. As a result, patients have a markedly increased risk of developing common-looking small-fiber peripheral neuropathy, ischemic stroke, myriad cardiac manifestations, and chronic renal disease. Some studies have found that about 0.5% of patients with stroke have GLA gene mutations. Specific therapy for Fabry disease now exists, including enzyme replacement and pharmacological chaperones. Modified enzyme replacement therapy with a long circulation half-life and substrate synthesis inhibitors is being tested. Current enzyme replacement therapy does not lower the risk of stroke. Clinical experience suggests that antiplatelet agents that are ADP-receptor blockers markedly reduce the risk of stroke in Fabry disease patients.
Key points
|
• Fabry disease is a genetic risk factor for stroke, small fiber neuropathy, heart, and kidney disease. | |
|
• It is X-linked, but heterozygote women may be symptomatic too. | |
|
• Fabry disease may explain approximately 0.13% of all strokes. | |
|
• The main complications of Fabry disease are nonspecific in character and, therefore, the disease is likely to be overlooked. | |
|
• Therapy includes specific intervention, such as enzyme replacement, and pharmacological chaperones. | |
|
• Current enzyme replacement therapy for Fabry disease, if initiated in adulthood, does not lower the risk of stroke and may not reduce the risk of cardiac death. |
Historical note and terminology
In 1898, German dermatologist Johannes Fabry (1860–1930) and English surgeon William Anderson (1842–1900) independently described the dermatological features of patients with what is now known as angiokeratoma corporis diffusum (56; 05).
Fabry reported skin lesions in a 13-year-old boy that initially were thought to represent purpura nodularis. After further study of this patient, the lesions were found to contain small-vessel aneurysms. Fabry classified this disease as “angiokeratoma corporis diffusum” (56). Fabry reported a follow-up on his original patient in 1916.
-
Watercolor of the histology of an angiokeratoma, from Fabry's original article (1898)
"Hematoxylin staining. Cutis papillae dark blue, almost violet, epidermis light blue, blood foci greenish-yellow, section through a larger nodule, near the blood papules the epidermal papillae are elongated. Some blood dropped ...
-
Watercolor of skin histology, using a carmine stain, from Fabry's original article (1898)
"Carmine coloring. Horny part of the epidermis. Epidermis dark red, dermis and subcutaneous connective tissue light red. An elongated, single-chamber hemorrhage in the cutis, apparently near a sebaceous duct, to the left of whi...
-
Watercolor of skin histology, using Weigert fibrin staining, from Fabry's original article (1898)
"Weigert fibrin staining. The incision has struck some hemorrhages of the dermis, also quite close to the epidermis; the contrast between blue fabric and brown colored blur is very striking; the section shows no tissue hypertro...
-
Watercolor of skin histology, using a carmine stain, from Fabry's original article (1898)
"Carmine staining. A comparatively large hemorrhage only in the epithelial part of the skin. tissue red, bleeding brown; part of the blood has fallen out, as is usually the case; the degree of secondary hypertrophy can be clear...
-
Watercolor of the histology of a hemorrhagic papule, using H&E staining, from Fabry's original article (1898)
"Hematoxylin and eosin staining. Here is a unicameral small and tapered hemorrhagic papule." (Source: Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis [Purpura papulosa haemorrhagica Hebrae]. Archiv für De...
-
Watercolor of the histology of a subcutaneous hemorrhage, using Taenzer's orcein staining, from Fabry's original article (1898)
"Hemorrhage in the area of a fat lobe in the subcutis; the blood here clearly contrasts with the tissue; the preparation shows that the bleeding is confined within one acinus and does not spread to neighboring ones." (Source: F...
-
Watercolor of the histology of venous congestion, using Taenzer's orcein staining, from Fabry's original article (1898)
"Taenzer's orcein staining shows a dilated vein due to blood congestion." (Source: Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis [Purpura papulosa haemorrhagica Hebrae]. Archiv für Dermatologie und Syph...
-
Watercolor of the histology of vascular congestion, using carmine staining, from Fabry's original article (1898)
"Carmine staining shows a club-shaped, distended small artery due to congestion." (Source: Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis [Purpura papulosa haemorrhagica Hebrae]. Archiv für Dermatologie ...
-
Angiokeratomas in Fabry disease, from Fabry's original article (1898)
Photograph of patient Emil Honke at the age of 13 years. (Source: Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis [Purpura papulosa haemorrhagica Hebrae]. Archiv für Dermatologie und Syphilis 1898;43:187-...
-
Angiokeratomas in Fabry disease, from Fabry's follow-up article (1916) on his original case
Photograph of patient Emil Honke in 1915 at the age of 30 years. (Source: Fabry J. Zur Klinik und Ätiologie des Angiokeratoma. Archiv für dermatologische Forschung 1916;123[2]:294-307. Photograph restored by Dr. Douglas J Lansk...
Anderson also diagnosed similar skin lesions in a 39-year-old male as angiokeratoma (05). This patient had albuminuria in addition to other clinical features that Anderson argued might be due to a systemic process rather than a disease limited to the skin. In 2016, Gaggl and colleagues published an extended pedigree in which Anderson's original case was the propositus; the pedigree spans seven generations and includes six affected males and seven obligate female carriers (61). The pedigree is consistent with an X-linked recessive trait.
-
Section of angiectasis (vascular ectasia), from Anderson's original article (1898)
"1, stratum corneum of epidermis; 2, stratum Malpighi; 3, papillary layer of dermis; 4, angiectasis, occupied by coagula and blood-corpuscles; 5, angiectasis, with dissepiment (ie, a partition in a part or organ; a septum); 6, ...
-
Pedigree of the patient with Fabry disease reported by Anderson (1898)
The pedigree spans seven generations and includes six affected males and seven obligate female carriers. Symbols: circle, female; square, male; dotted circle, obligate female carrier; filled square, diseased male; arrow, propos...
The disease remained under the purview of dermatologists until 1947, when Pompen and colleagues described the first postmortem pathological examination on two affected brothers. This report documented the existence of abnormal storage vacuoles in blood vessels throughout the body and established that Fabry disease was a generalized storage disorder (119).
Various studies in the 1960s documented pedigrees consistent with an X-linked recessive inheritance pattern, most notably a study from the University of Wisconsin by German-American medical geneticist John M Opitz (b 1935) and colleagues (35; 175; 39; 112; 93).
Sweeley and Klionsky first elucidated the biochemical nature of the storage material in Fabry disease (157). They determined that the accumulating substance consisted primarily of two glycosphingolipids, globotriaosylceramide and galabiosylceramide. Brady and colleagues showed that Fabry disease was caused by a deficiency of the enzyme alpha-galactosidase A, resulting in the storage of glycolipids containing a terminal alpha-galactosyl residue such as globotriaosylceramide (18).
The molecular structure of the gene encoding alpha-galactosidase A, GLA, was first identified as the full-length cDNA clone in 1986 (14), and the entire gene organization was determined in 1989 (89).
Following the development of enzyme replacement therapy for Gaucher disease, the production of glucocerebrosidase and the mechanisms of lysosomal targeting were used as a blueprint to produce recombinant human alpha-galactosidase, which received regulatory approval from the European Union in 2002 and FDA approval in 2003.
Clinical manifestations
Presentation and course
Patients with Fabry disease are typically divided into a severe, classic phenotype, which is caused by mutations that are associated with no (or less than 3%) residual alpha-galactosidase A activity and a generally milder nonclassical phenotype with variant, atypical, or late-onset mutations associated with definite residual activity of up to 30% of mean normal values (153; 06).
In affected hemizygous males with the classic phenotype, clinical symptoms usually begin in late childhood or adolescence with the development of neuropathic pain in the extremities (acroparesthesia), poor heat and exercise tolerance, angiokeratoma, hypohidrosis, corneal and lenticular opacities (cornea verticillata), and psychosocial problems (127). Because of the storage of glycolipid in the vascular system, progressive cardiac, renal, and cerebral involvement follows, mostly during the second to fourth decades. Late complications of the disease include deafness and tinnitus, stroke, cardiac conduction disturbances, hypertrophic cardiomyopathy with left ventricular hypertrophy, valvular heart disease, gastrointestinal problems, and chronic renal failure.
Nonclassical Fabry disease is characterized by a more variable disease course, in which patients are generally less severely affected, disease onset is delayed, and disease manifestations may be limited to a single organ (06; 32). Patients with Fabry disease identified in screening studies of individuals with stroke, renal failure, or cardiomyopathy often have the nonclassical phenotype (06).
Despite the X-linked inheritance pattern of Fabry disease, women often have signs and symptoms of Fabry disease due to skewed X chromosome inactivation, although they are usually less severely affected than men (96; 48; 06).
Clinical features of Fabry disease in 20 children (13 boys and seven girls) were reported in a Russian study, unfortunately without indication of the frequencies separately for boys and girls; in descending order of frequency were acroparestheia, proteinuria, angiokeratomas, hypohidrosis, gastrointestinal features (abdominal pain or discomfort, diarrhea), keratopathy, cardiac features (left ventricular hypertrophy, chest pain), and hearing loss (136). Another common early sign of Fabry disease in both boys and girls is low skeletal muscle mass (94).
Dermatologic findings. Angiokeratomas consist of clusters of individual ectatic blood vessels covered by a few layers of skin. These lesions are flat or slightly raised, dark red to blue in color, and are usually located in the groin, buttocks, upper legs, and umbilical regions. The angiokeratomas become apparent in childhood and gradually increase in size and number over the years. Angiectasias may also occur in the oral mucosa, pinna of the ear, conjunctiva, and retina.
-
Angiokeratoma: multiple small pink to dark-red spots on the lateral trunk
(Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17[1]:...
-
Red-purple, nonblanching vascular skin lesions (angiokeratoma) on the umbilicus of a patient with Fabry disease
Angiokeratoma are usually distributed on the buttocks, groin, umbilicus, upper thighs (bathing trunk distribution), and, occasionally, on the lips and oral mucosa. (Source: Burlina AP, Sims KB, Politei JM, et al. Early diagnosi...
-
Angiokeratoma: multiple 1- to 5-mm pink to dark-red or blue-black spots with hyperkeratotic surface on the scrotum
(Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17[1]:...
-
Red-purple, nonblanching vascular skin lesions (angiokeratoma) on the lips and oral mucosa of a patient with Fabry disease
Angiokeratoma are usually distributed on the buttocks, groin, umbilicus, upper thighs (bathing trunk distribution), and, occasionally, on the lips and oral mucosa. (Source: Burlina AP, Sims KB, Politei JM, et al. Early diagnosi...
-
Linear telangiectasia on the lower lip mucosa of a patient with Fabry disease
(Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17[1]:...
-
Linear telangiectasia on the pinna of a patient with Fabry disease and sensorineural hearing loss
(Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17[1]:...
Cardiac findings. Glycosphingolipid accumulation within myocardium, heart valves, conduction pathways, and coronary vessels occurs in hemizygous males. Hypertrophic cardiomyopathy may occur without other clinical manifestations of Fabry disease in hemizygous males (114). On the other hand, diastolic dysfunction can occur prior to the presence of left ventricular hypertrophy (177). Mitral valve insufficiency is a common occurrence, and arrhythmias and electrocardiogram changes are often noted. Small vessel myocardial ischemia and infarction are frequent late manifestations of this disorder (30). Sudden cardiac death is the more common cause of death in patients with Fabry disease (09).
-
EKG findings in Fabry disease: bifascicular and first-degree atrioventricular blocks and EKG criteria of left ventricular hypertrophy
EKG findings in a 72-year-old male. (Source: Azevedo O, Cordeiro F, Gago MF, et al. Fabry disease and the heart: a comprehensive review. Int J Mol Sci 2021;22[9]:4434. Creative Commons Attribution 4.0 International [CC BY 4.0] ...
-
EKG findings in Fabry disease: nonsustained ventricular tachycardia in 24-hour Holter monitoring
EKG findings in a 76-year-old male. (Source: Azevedo O, Cordeiro F, Gago MF, et al. Fabry disease and the heart: a comprehensive review. Int J Mol Sci 2021;22[9]:4434. Creative Commons Attribution 4.0 International [CC BY 4.0] ...
Pulmonary findings. Respiratory symptoms are usually not considered prominent manifestations of Fabry disease, but with age, patients complain of dyspnea, cough, and wheezing that is independent of their smoking status (21). This population also has a higher incidence of spontaneous pneumothorax and, occasionally, hemoptysis. The pulmonary symptoms are postulated to be due to fixed narrowing of airways from glycosphingolipid accumulation.
Renal findings. Progressive glycosphingolipid accumulation within the renal glomeruli and tubules and the vasculature is associated with proteinuria and gradual renal failure. Inspection of the urine with polarized light will often demonstrate casts and “Maltese crosses,” which are birefringent lipid globules. Deterioration of renal function develops, with azotemia and death occurring in the third to fifth decades, unless treatment with chronic hemodialysis or renal transplantation is provided (19; 138).
Pathologic findings of renal involvement of Fabry disease in kidney biopsy (light microscopy)
Hematoxylin-eosin staining, X400 magnified. (Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey ...
Gastrointestinal findings. Among 48 adult patients with Fabry disease and gastrointestinal manifestations, abnormal bowel habits and abdominal pain were the most common symptoms; bloating, nausea, vomiting, and reflux were also prevalent (12). Neurologic manifestations were found in 96%, along with their gastrointestinal manifestations. Dysmotility was found in fewer than 35% of wireless motility capsule tests. Colon transit time was associated with constipation severity. Gastrointestinal symptoms were associated with reduced quality of life, anxiety, and reduced work or productivity.
Ophthalmological findings. Corneal opacity that can be seen only by slit-lamp examination is usually the first ocular abnormality. These corneal changes (present in essentially all hemizygous Fabry patients) first appear as a mild generalized clouding in the subepithelial corneal layer and may progress to form whorled streaks ("cornea verticillata") (173).
Cornea verticillata (also called vortex keratopathy, whorl keratopathy, or Fleischer vortex) describes a whorl-like pattern of golden brown or gray opacities in the corneal epithelium. "Verticillata" is from the Latin noun “verticillus,” meaning "whorl.” Usually asymptomatic, it is caused by the deposition of metabolic substrates or disease byproducts in the basal epithelial layer of the cornea in Fabry disease. Cornea verticillata is not specific to Fabry disease, however, as it may also occur with other diseases (eg, multiple myeloma, neurotrophic keratitis, Lisch corneal dystrophy, epidemic keratoconjunctivitis, and iron deposition after radial keratotomy) and as a complication of some drugs (eg, amiodarone, atovaquone, chloroquine/hydroxychloroquine, gentamicin, gold salts, indomethacin, meperidine, perhexiline maleate, phenothiazines such as chlorpromazine, suramin, tamoxifen, tilorone, and the tyrosine kinase inhibitors vandetanib and osimertinib) (134). Nevertheless, cornea verticillata is most often associated with Fabry disease or amiodarone use. Chloroquine and hydroxychloroquine increase the intralysosomal pH and may cause corneal pathology by reducing the activity of the alpha-galactosidase A enzyme (76).
-
Cornea verticillata (a bilateral, whorl-like corneal pattern of cream-colored lines) in a patient with Fabry disease
(Source: Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 2011;11:61.)
Lenticular opacities may occur in approximately 30% of affected males and consist of granular anterior capsular and subcapsular deposits, or a characteristic posterior capsular spoke-like opacity, or “Fabry cataract” (16). The corneal and lenticular opacities, however, do not interfere with vision.
Retinal and conjunctival lesions, manifesting as tortuous and dilated vessels, may occur as part of a diffuse systemic vascular involvement. Ischemic optic neuropathy may occur secondary to cilioretinal artery occlusion or central retinal artery occlusion (54).
-
Vascular tortuosity, telangiectasias, and aneurysmal changes of the conjunctival vessels in the left eye of a patient with Fabry disease
(Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17[1]:...
-
Linear telangiectasia in the conjunctiva of a patient with Fabry disease
(Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17[1]:...
-
Fundus examination of a patient with Fabry disease showing increased retinal vascular tortuosity in the right eye
(Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17[1]:...
Corneal verticillata, hyper-reflective foci on optical coherence tomography, conjunctival vessel malformation, and retinal vessel tortuosity are prevalent, characteristic, and easily accessible in patients with Fabry disease and should be considered among the clinical diagnostic criteria for the disease (173).
Peripheral nervous system findings. Patients with Fabry disease suffer from a length-dependent small-fiber neuropathy (149; 95; 22). Dorsal root ganglia may become swollen (22).
-
Photomicrographs of frozen skin sections (50 μm) from a patient with Fabry disease
Samples immunoreacted with PGP 9.5 and were processed for fluorescence microscopy with Cy3 labeled secondary antibodies. Note the lack of intraepidermal nerve fibers and persistence of fibers pertaining to the subepidermal nerv...
The most dramatic symptom in males, and often in females, affected with Fabry disease is pain in the extremities (111; 96). This is usually described as an intense burning or lancinating pain in the fingers or toes. There may also be mild persistent numbness and paresthesias in the extremities (acroparesthesia), interspersed with episodic excruciating pain. The painful crises may last for several days and may be associated with fever and an increased erythrocyte sedimentation rate. Decreased cold perception and, to a lesser extent, warm perception is a hallmark of this neuropathy (95). Exposure to cold is particularly painful (69). Autonomic nervous system dysfunction commonly manifests as chronic diarrhea, constipation, nausea, exaggerated gastrocolic reflex, reduced cutaneous flare response, and hypohidrosis (25). Priapism has been described in some patients, mostly children; it may be due to increased neuronal nitric oxide synthase (and probably endothelial nitric oxide synthase) content and the consequent elevated nitric oxide production and high arterial blood flow in the penis (100).
Cochleovestibular findings. Individuals with Fabry disease have an increased prevalence of peripheral vestibular disorders (176). Hearing impairment and vertigo are common findings, especially in males with Fabry disease (128).
Central nervous system findings. The symptoms related to the cerebrovascular complications of Fabry disease are no different than stroke symptoms from any other etiology. They include hemiparesis, vertigo, diplopia, dysarthria, nystagmus, headache, ataxia, memory loss, and hemisensory loss (115). The vertebrobasilar system was affected in 67% of hemizygotes and 60% of heterozygotes, with elongation and tortuosity of vertebral and basilar vessels noted angiographically (58). A study using MR angiography showed that the basilar artery is enlarged in male patients with Fabry disease as a whole (58). MR angiography often shows that the basilar artery is enlarged and tortuous (dolichoectasia) in male patients with Fabry disease (58; 162; 55). Indices of abnormal cerebral autoregulation on transcranial Doppler ultrasonography are significantly impaired in Fabry disease (113; 124).
In a quantitative MRI study of 50 Fabry hemizygotes, progressive cerebrovascular involvement in small- to medium-size vessels occurred over time (36). In this study, there were no patients younger than 26 years of age who had cerebrovascular disease, but all patients over 54 years of age had cerebrovascular disease, although usually these lesions were clinically silent. Strokes are common, can be the presenting symptom, and can occur in female heterozygotes as well (115; 152; 178).
-
Brain MRI findings in Fabry disease: acute small-junctional infarct (DWI)
Spectrum of diffusion-weighted brain MRI findings in a 51-year-old male patient with Fabry disease. Arrow indicates acute small-junctional infarct. (Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the reco...
-
Brain MRI findings in Fabry disease: chronic left mid-pons perforating infarcts (T2-weighted)
Spectrum of T2-weighted brain MRI findings in a 51-year-old male patient with Fabry disease. Chronic left mid-pons perforating infarcts (lacune type, arrow). (Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion o...
-
Brain MRI findings in Fabry disease: accumulation of small basal perforating infarcts
Spectrum of brain MRI findings in a 51-year-old male patient with Fabry disease. Accumulation of small basal perforating infarcts: (1) right thalamic lesion; (2) emergence of left caudate lesion in 1-year interval. (Source: Ezg...
White matter lesions on MRI are common and are not typically accompanied by neurologic or cognitive abnormalities (90). Cerebral microbleeds were found by brain MRI in 30% of patients (87). In addition, these white matter lesions do not regress with enzyme replacement therapy (156). Asymptomatic white matter lesions on brain MRI were found in 16% of children with Fabry disease (97).
Brain MRI findings in Fabry disease: white matter hyperintense lesions (FLAIR)
Spectrum of FLAIR sequence brain MRI findings in a 51-year-old male patient with Fabry disease. (Source: Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and ad...
Heterozygous females. Heterozygous females may have variable manifestations of Fabry disease that can range from asymptomatic to as severe as a male with classic Fabry disease (123; 75; 07; 48; 17; 71; 70; 68; 165). Approximately 70% to 80% of affected females will have corneal opacities, but only rarely will cataracts be noted. In approximately 30% of females, a few angiokeratomas may be present in the characteristic location. Intermittent pain and paresthesia may occur and, rarely, cardiac and renal symptoms may develop. A few heterozygotes have had clinical symptoms comparable to those found in affected males, thought to be due to skewed X-inactivation (48). In a female monozygotic twin pair, wherein one girl was affected with Fabry disease and the other was asymptomatic, uneven X-inactivation and discordant gene expression were found to explain the clinical differences in these identical siblings (123).
Prognosis and complications
Fabry disease has a high cost and healthcare resource use burden and reduced quality of life compared with healthy populations (79). The following factors were identified as independent predictors of decreased health-related quality of life: classic phenotype, kidney and heart disease, stroke or transient ischemic attack, depression, and burning limb pain (172). Enzyme replacement therapy and chaperone therapy were independent determinants of improved health-related quality of life.
Most untreated hemizygous males die by 40 to 50 years of age. The median survival age of males with Fabry disease is 50 to 55 years (19; 138). Death is usually a consequence of renal failure, heart disease, or sometimes stroke (19); however, myocardial ischemia may also cause fatal complications (30). Heterozygous females have mild symptoms and a wide spectrum of disease complications. Clinical manifestations of Fabry disease can range between subtle subclinical manifestations such as corneal opacities and classic Fabry disease as described before. MRI abnormalities in the kidneys have been observed in affected males and in female carriers; however, this latter group presents a lower incidence than classically affected males (65). Cerebrovascular manifestations have been observed in carrier females (152). Therefore, Fabry disease in heterozygotes has a wide spectrum (66).
Clinical vignette
A 12-year-old boy presented to the child neurology clinic with a history of painful extremities after exercising on warm days. This began 1 to 2 years earlier and was similar to what his sister and mother had experienced at the same age. Both mother and sister, however, had milder symptoms, and at the age of 43 years, the mother was no longer troubled by this symptom. The child had also complained of diarrhea and cramping following meals. The family history was significant for a maternal uncle who died at the age of 47 and a grandfather who died at the age of 54 from complications of myocardial infarctions and multiple strokes. The clinical examination revealed a painful peripheral neuropathy affecting the distal lower extremities. Three angiokeratomas were present around the umbilicus, groin, and buttock.
Examination of the eyes demonstrated a slight clouding of the corneas, but no lenticular opacities were observed. Because of the possibility of an X-linked disease, the pathological studies obtained from the maternal uncle were reviewed. Tissue taken from the dorsal root ganglia showed an accumulation of lipids in the small sensory neurons consistent with Fabry disease in the uncle.
Leukocyte alpha-galactosidase A enzyme activity from the boy was low, thus confirming the diagnosis of Fabry disease.
Biological basis
Etiology and pathogenesis
Fabry disease is caused by a deficiency of the enzyme alpha-galactosidase A.
Alpha-galactosidase homotetramer + NAG (green-red) + mannose (l blue-red), Mortierella vinacea
(Source: Deposition authors: Fujimoto Z, Kaneko S, Kobayashi H; visualization author: User:Astrojan on May 18, 2019 http://www.rcsb.org/structure/...]. Creative Commons Attributi...
Genetics. Fabry disease has often been regarded as an X-linked recessive disorder, and most published pedigrees are consistent with that form of inheritance (33).
-
Family pedigree of a patient with Fabry disease showing the x-linked pattern of inheritance (1)
The index patient (propositus) is marked with a black arrow. Affected males are indicated by solid black squares; female carriers are indicated by a round black circle within the larger circle denoting a woman. Numbers within s...
-
Family pedigree of a patient with Fabry disease showing the x-linked pattern of inheritance (2)
The index patient (propositus) is marked with a black arrow. Affected males are indicated by solid black squares; female carriers are indicated by a round black circle within the larger circle denoting a woman. Numbers within s...
-
Family pedigree of a patient with Fabry disease showing the x-linked pattern of inheritance (3)
The index patient (propositus) is marked with a black arrow. Affected males are indicated by solid black squares; female carriers are indicated by a round black circle within the larger circle denoting a woman. Numbers within s...
-
Family pedigree of a patient with Fabry disease showing the x-linked pattern of inheritance (4)
The index patient (propositus) is marked with a black arrow. Affected males are indicated by solid black squares; female carriers are indicated by a round black circle within the larger circle denoting a woman. Numbers within s...
-
Family pedigree of a patient with Fabry disease showing the x-linked pattern of inheritance (5)
The index patient (propositus) is marked with a black arrow. Affected males are indicated by solid black squares; female carriers are indicated by a round black circle within the larger circle denoting a woman. Numbers within s...
However, the observation that female heterozygotes are frequently affected, albeit usually less severely than affected males, argues that Fabry disease could or should be considered X-linked dominant with reduced penetrance (96; 75; 07; 48; 06; 17; 71; 70; 68; 165; 77). As with many other X chromosome disorders, it has also been argued that Fabry disease should instead be characterized simply as inherited in an X-linked manner, without distinction as to being recessive or dominant (46).
-
Clinical manifestations of Fabry disease in female heterozygotes and its multiorgan involvement
(Source: Izhar R, Borriello M, La Russa A, et al. Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations. Genes [Basel] 2023;15[1]:37. Creative Commons Attribution 4.0 International [CC BY 4.0]...
Pathological findings. Multiple organs are affected in Fabry disease, but the major pathological alterations occur in the cardiovascular and renal systems secondary to glycosphingolipid accumulation.
Skin. The skin lesions consist of superficial telangiectasias and angiomas. Larger angiomas may be associated with elevation, hypertrophy, and hyperkeratosis, explaining the use of the term “angiokeratoma.” Other pathological changes may include atrophy or reduction in the number of sweat and sebaceous glands, as well as lipid accumulation in sweat glands (64).
Heart. Glycosphingolipid accumulation occurs in myocardial cells and valvular fibrocytes (41), causing the hypertrophy of the chamber walls, along with valvular involvement. Coronary vessels are also affected by lipid storage within their endothelial cells.
Lungs. Pathological studies have demonstrated laminated inclusions in ciliated epithelial cells, goblet cells, capillary endothelium, type II pneumocytes, and in pulmonary and bronchial smooth muscles (21).
Kidney. The first lipid deposition in Fabry kidney begins in endothelial and epithelial cells of the glomerulus and later affects proximal tubules and interstitial cells (108). Eventually, renal vessels also show glycosphingolipid accumulation.
Eye. The eye demonstrates glycosphingolipid deposits within the ocular vessels, iris, and connective tissue of the lens and cornea (59). A corneal dystrophy is seen, thought to be secondary to subepithelial ridges or reduplication of the basement membrane (59).
Nervous system. The CNS is affected by a cerebral vasculopathy (138) and accumulates lipids in several groups of neurons, many belonging to the autonomic nervous system. These areas involved include the supraoptic, preoptic, and paraventricular nuclei, nucleus basalis of amygdala, anterior thalamus, subiculum of hippocampus, Edinger-Westphal nucleus, mesencephalic nucleus of the fifth cranial nerve, substantia nigra, salivary nuclei, dorsal nucleus of the vagus, nucleus gracilis and cuneatus, reticular substance of pons and medulla, and intermediolateral cell columns of the thoracic cord (120; 82; 43). Peripheral nervous system structures that show lipid accumulation include the small ganglion cells in dorsal horn and loss of small myelinated and unmyelinated nerves (111; 24).
See Table 1 below for chemical storage.
Table 1. Glycosphingolipids that Accumulate in Fabry Disease
|
Globotriaosyl-ceramide |
{Gal(alpha1---> 4)Gal(beta1---> 4) |
|
Galabiosyl-ceramide |
{Gal(alpha1---> 4)Glc(beta1--> 1')Cer} |
|
Blood Group B glycolipid |
{Gal(alpha1---> 3)Gal(2< ---1alphaFuc) |
|
Blood Group B1 glycolipid |
{Gal(alpha1---> 3)Gal(2< ---1alphaFuc) |
Globotriaosylceramide accumulates in many tissues, including kidney, aorta, spleen, liver, autonomic ganglia, lymph nodes, striated muscle, and prostate (43). Within the central and peripheral nervous systems, histologic lipid staining is caused by storage of globotriaosylceramide (82). Using immunocytochemical techniques with a monoclonal antibody to globotriaosylceramide, more widespread neuronal storage of this lipid could be demonstrated in layers 5 and 6 of the neocortex, pigmented neurons in the substantia nigra, substantia gelatinosa, and motor neurons (45). Despite this neuronal “accumulation,” Fabry disease is not a primary neuronal disorder. Typically, the only evident CNS neuronal dysfunction or loss occurs secondarily in association with ischemic lesions (103). Galabiosylceramide (digalactosylceramide) appears to be more tissue-specific because it is stored primarily in kidney, pancreas, right heart structures, lung, and urinary sediment (43). Patients with blood groups B or AB, who possess the blood group B antigen, were previously thought to have a more severe form of Fabry disease, but more recent studies dispelled this notion (92).
Biochemistry of alpha-galactosidase A. The biochemical defect in Fabry disease is the deficiency of the alpha-galactosidase A enzyme.
Mutations in the GLA gene alter the structure of alpha-galactosidase A and lead to its markedly deficient or absent activity (34).
Mutations in the GLA gene alter the structure of alpha-gal-A and lead to its markedly deficient or absent activity
(Left side) Functional alpha-gal-A activity in a person with no mutation in GLA gene or absent activity. As a result, there is no accumulation of unwanted substrate in the lysosome. Also, the enzyme is responsible for removing ...
The glycosphingolipids (such as globotriaosylceramide, digalactosylceramide, and galabiosylceramide) have in common a terminal alpha-galactosyl moiety that is cleaved by the alpha-galactosidase A enzyme.
Thus, a deficiency or defect in the enzyme results in the accumulation of various glycosphingolipids with terminal alpha-D-galactosyl residues, including globotriaosylceramide and digalactosylceramide.
The mature enzyme is a 46 kd protein that forms a homodimeric structure of approximately 101 kd and functions optimally with an artificial substrate at a pH of 4.6. The C-terminal region of the alpha-galactosidase A is important for the regulation of the enzyme because a deletion of 12 or more amino acids from the C-terminus results in a complete loss of enzyme activity (101). The enzyme requires the presence of saposin B, a sphingolipid activator protein also known as sphingolipid activator protein-1. Saposin B, one of a family of activator proteins encoded by the same gene on chromosome 10, acts as a detergent for the protein-lipid complex (110). Saposin B is also required for the function of two other lysosomal enzymes, beta-galactosidase (deficient in GM1 gangliosidosis) and arylsulfatase-A (deficient in metachromatic leukodystrophy) in addition to stimulating the hydrolysis of over 20 glycolipids.
Molecular genetics of alpha-galactosidase A. The gene encoding alpha-galactosidase A, GLA, is localized to Xq22.1 (164). The gene is 12 kbp in length and contains seven exons (ranging from 92-291 bp) and six introns (ranging from 0.2 to 3.8 kbp). The full-length cDNA has 1437 bp encoding a mature 398 amino acid subunit and a 31 amino acid signal peptide (89). The gene is unusual as it does not have a 3' untranslated region and has 12 Alu repetitive elements that represent about 30% of the 12 kbp gene (15). Despite this abundance of Alu repeat elements, there has been only one reported deletion caused by an Alu-Alu recombination (88). In the first exon, there is a 60 bp 5' untranslated sequence prior to the initiation codon containing three polymorphic variants (37).
Defects in the GLA gene in Fabry disease. In a study of 130 Fabry families, six rearrangements of the gene encoding alpha-galactosidase A were identified by Southern blot analysis (13). Five of these abnormalities were deletions (four in exon 2), and one was caused by a duplication. At present, over 500 mutations, including deletions, insertions, partial duplications, splice junction consensus sight alterations, complex mutations involving more than one mutational event, and single base substitutions causing nonsense or missense mutations, have been reported (The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff). In asymptomatic or mildly affected cardiac variants, however, only missense mutations that expressed residual alpha-galactosidase A activity were identified (42). A genotype-phenotype correlation has been difficult to establish, but some mutations such as the p.N215S mutation seen in asymptomatic and mild cardiac variants and the p.D264V noted in patients with pulmonary symptoms suggest that some genotypes may predict the clinical course. Although most of the mutations are “private,” or confined to a single family, some common mutations such as p.R227Q and p.R227X were identified (50). A very large kindred in Nova Scotia with the p.L143P mutation has been described (44). Common sites for point mutations include CpG dinucleotide regions (51). Codons 111 to 122 appear to be a deletion "hot spot" (53). Exon 7 appears to be a region prone to gene rearrangements (50). The IVS4 + 919G > A mutation, a highly prevalent splice mutation among Han Chinese, has mainly cardiac consequences, but its clinical expression may depend in part on heart-related modifier genes (80). In Taiwan, this mutation has a prevalence of 1 of 875 in males and 1 of 399 in females. Despite the existence of some geographic and ethnic regions with founder mutations, new private mutations continue to be discovered, suggesting significant heterogeneity in the molecular mutations causing Fabry disease in various families (141).
Although disease-associated point mutations in protein-coding gene regions usually cause translational perturbations and result in premature chain termination, amino acid substitutions, or overall altered sequence alterations downstream from the mutation site, nucleotide exchanges at the border between introns and exons can affect splicing behavior and lead to abnormal pre-mRNA processing (01). For example, exonic mutations c.194G>T and c.358C>G lead to the use of alternative donor splice sites at exon 1 and exon 2, respectively, and the mutations c.548G>T and c.638A>T lead to significant exon 4 skipping (01).
In some families, there may be considerable phenotypic heterogeneity even with the same mutation (163).
Pathophysiology of Fabry disease. Most glycosphingolipids are synthesized in the liver or bone marrow. Globotriaosylceramide appears to be transported from hepatocytes by low- and high-density lipoproteins and taken up by other cells through high-affinity lipoprotein receptors. Globoside, a major precursor of globotriaosylceramide, is produced to a large extent from the senescence of erythrocyte membranes. The turnover of membrane glycosphingolipids is a major substrate burden in Fabry disease. In many organs, such as the vascular endothelium, muscle, and kidney, glycosphingolipid storage may occur either from endogenous production or, less likely, secondarily through active uptake and diffusion of circulating glycolipids. Globotriaosylceramide accumulation also occurs in nervous system structures with permeable blood-brain barriers, such as the choroid plexus, circumventricular organs, and dorsal root ganglion (82). Other cerebral nuclei that do not have a permeable blood-brain barrier are hypothesized to store globotriaosylceramide, because of either site-specific differences in metabolism or selective uptake and transfer of this lipid (82; 45).
A prothrombotic state was identified in Fabry disease (38) in association with dysfunction of endothelial nitric oxide synthase and increased release of reactive oxygen species associated with cerebral hyperperfusion at rest (105; 106). Hyperperfusion at rest was confirmed in an arterial spin-labeling MRI study (116). A general inflammatory state is common (84).
Inflammation and exosomes. The autophagic process can be divided into four mechanistically different phases: (1) initiation, (2) vesicle formation (elongation and closure), (3) autophagosome-lysosome fusion, and (4) breakdown of the cargo (34). These steps begin with the appearance of an isolation membrane in the cytoplasm, known as a phagophore, that engulfs a portion of the cytoplasm, expands, and seals itself to form a double-membrane structure, the autophagosome. The autophagosome may also fuse with endosomes or multivesicular bodies, forming a structure known as an amphisome. The outer membrane of the autophagosome fuses with the lysosome, giving origin to an autolysosome, in which all the autophagosome contents are degraded by acidic lysosomal hydrolases.
Given the role of lysosomes in immune cell physiology, Fabry disease can have impaired inflammatory and immunological responses (34). Globotriaosylceramide accumulation potentiates the production of pro-inflammatory mediators (34). Globotriaosylceramide and globotriaosylsphingosine alter the levels of soluble factors and signaling receptors as well as the inflammatory-cell profile in Fabry disease (34). In parallel, exosomes function as mediators of the immune and inflammatory pathways, in part because extracellular vesicles are capable of transporting cytokines and other immunomodulatory molecules (34). Indeed, exosomes can carry anti- and pro-inflammatory cytokines both on their lumens and associated with their membranes.
-
Exosomes function as mediators of the immune and inflammatory pathways
Exosomes can carry anti- and pro-inflammatory cytokines both on their lumens and associated with their membranes. Several cytokines have been shown to be preferentially enriched within exosomes, including interleukin-2, -4, -10...
Epidemiology
Fabry disease is an X-linked disorder (X-linked recessive or X-linked dominant with variable penetrance in females) that maps to Xq22 (164). Many patients are not diagnosed because of the nonspecific nature of the complications and the involvement of only one organ system (“atypical Fabry disease”).
The disease is relatively rare, with an estimated prevalence of 1 in 40,000 (43). Although most reported cases have occurred in Caucasians, a variety of ethnic groups have been affected with the disease. Findings in newborn screening studies suggest that the prevalence of Fabry disease may be as high as 1 in 4600 births (154). A newborn screening study of 219,973 samples in Illinois found an estimated prevalence of Fabry disease of 1 in 8454, including the p.A143T variant, and 1 in 10,000 without including this variant (23); the p.A143T variant was by far the most common. In a newborn screening program in Western Japan, no patients with the A143T variant were identified (137).
Some studies have reported the prevalence of Fabry disease among patients with stroke, patients undergoing dialysis, and patients with hypertrophic cardiomyopathy (131; 91). In a re-analysis of 63 studies that screened 51,363 patients corrected for real pathogenic mutations, the revised prevalence estimates were 0.21% for male and 0.15% for female hemodialysis patients, 0.94% for males and 0.90% for females with hypertrophic cardiomyopathy, and 0.13% for male and 0.14% for female stroke patients (47). Fabry disease is not common among patients with other forms of heart disease (146).
In a systematic review and meta-analysis of studies of the prevalence of Fabry disease in patients with chronic kidney disease, 55 studies were included, involving a total of 84,062 individuals (91). Of these, 251 cases were positive for Fabry disease; a third of the reported GLA variants were of a benign phenotype (38%), followed by classical phenotype (32%), late-onset (16%), and of uncertain significance (15%). The overall prevalence among dialysis patients was 0.10%, 0.28% among patients with kidney transplantation, and 0.17% among those without kidney replacement therapy. The prevalence of kidney involvement in females with Fabry disease is lower.
In another systematic review and meta-analysis of screening studies, the pooled prevalence of Fabry disease was 1.2% in patients with left ventricular hypertrophy or hypertrophic cardiomyopathy (26 studies, 10,080 patients screened), 0.3% in end-stage renal disease/chronic kidney disease (38 studies, 62,050 patients screened), 0.7% in stroke (25 studies, 15,295 patients screened), 0.7% in cardiac conduction disturbance requiring a pacemaker (three studies, 1033 patients screened), 1.0% in small-fiber neuropathy (three studies, 904 patients screened), and 0.01% in newborns (15 studies; 11 108 793 newborns screened) (102).
Certain geographical areas have a high number of patients due to a founder effect; these include Nova Scotia (85) and possibly also Taiwan (29).
Prevention
Because of the low prevalence of the disease in the general population, carrier testing is not routinely performed. Screening of patients at risk has been proposed (08). In affected families, however, alpha-galactosidase enzyme analysis will diagnose hemizygous males, but only genetic analyses for GLA mutations can identify heterozygous females. It was previously thought that urinary glycolipid measurements could be used to determine carrier status in females by comparing the ratio of globotriaosylceramide and galabiosylceramide to hydroxy fatty acid glucosylceramide (26). However, globotriaosylceramide is also elevated in the urine of patients with heart disease who do not have any clinical, genetic, or biochemical evidence of Fabry disease (140). Interestingly, elevated levels of this glycosphingolipid along with elevation of other lipids are a risk factor for death in patients with common heart disease (140). The recognition of the disease or carrier status in different family members can then lead to appropriate genetic counseling. Because the disease is inherited as an X-linked disorder, hemizygous males are unable to pass the disease to their sons, but all of their daughters will be carriers. Heterozygous mothers can expect to have 50% of their sons be affected with the disease and 50% of their daughters be carriers.
Differential diagnosis
Confusing conditions
The complete clinical syndrome of Fabry disease in males, including angiokeratoma, painful peripheral neuropathy, and corneal dystrophy beginning in childhood, is characteristic. Other diseases, however, may be associated with angiokeratoma. Four dermatologic conditions have angiokeratoma as a major manifestation: (1) solitary or multiple angiokeratomas usually occur on the lower extremities following trauma; (2) angiokeratoma circumscriptum is usually characterized by a large solitary hyperkeratotic plaque that is first noted at birth or in early childhood and is more frequent in males; (3) angiokeratoma of Mibelli is more common in females, with childhood onset of hyperkeratotic vascular lesions over bony prominences; (4) the lesions of angiokeratoma of Fordyce are confined to the scrotum, although similar lesions have been described on the labia of older women (74). Angiokeratoma can also be seen in other metabolic disorders, such as neuraminidase deficiency, galactosialidosis, fucosidosis, GM1 gangliosidosis, and aspartylglucosaminuria (43).
Cornea verticillata is most often associated with Fabry disease or amiodarone use. It may also occur with other diseases (eg, multiple myeloma, neurotrophic keratitis, Lisch corneal dystrophy, epidemic keratoconjunctivitis, and iron deposition after radial keratotomy) and as a complication of some drugs (eg, atovaquone, chloroquine/hydroxychloroquine, gentamicin, gold salts, indomethacin, meperidine, perhexiline maleate, phenothiazines such as chlorpromazine, suramin, tamoxifen, tilorone, and the tyrosine kinase inhibitors vandetanib and osimertinib) (169; 76; 134).
Renal disease consisting of proteinuria, lipiduria, and electron-dense lysosomal granules, which mimic the renal manifestations of Fabry disease, may be induced by exposure to silica (11).
Uncommonly, Fabry disease may present with muscle pain and weakness in the extremities, with an increasing erythrocyte sedimentation rate and C-reactive protein, leading to an erroneous diagnosis of polymyalgia rheumatica (174).
Diagnostic workup
A diagnostic algorithm has been proposed, which utilizes clinical features, such as early-onset symptoms, late-onset symptoms, and very specific symptoms (ie, cornea verticillata and angiokeratomas) or family history of Fabry disease to dictate further testing of enzyme activity in males or gene mutation analysis in females (55). It is unclear which patients with stroke, kidney disease, or heart disease should be screened for Fabry disease (160; 132).
The diagnostic approach varies for male and female patients (03; 77).
-
Algorithm for diagnosing women affected or suspected of having Fabry disease
Abbreviations: ALGLA, alpha-galactosidase A; FD, Fabry disease; GB3, globotriaosylceramide.
(Source: Izhar R, Borriello M, La Russa A, et al. Fabry disease in women: genetic basis, available biomarkers, and clinical mani...
To date, female patients have been underrecognized and undertreated in several countries (135; 77).
Analysis of enzyme activity and accumulating metabolites. The most effective method of diagnosing Fabry disease is measurement of alpha-galactosidase A enzyme activity in males. This enzyme may be measured in plasma, tears, leukocytes, cultured fibroblasts, or transformed lymphoblasts (40). Affected hemizygous males typically have no detectable galactosidase A activity, whereas others have enzyme activity up to 30% to 35% of mean normal. Female heterozygotes can have low or normal enzyme activity, and they do often have elevated globotriaosylceramide levels in the urine, but definitive diagnosis of Fabry disease in an affected female can only be made via mutation analysis of the GLA gene (66).
Demonstration of elevated globotriaosylceramide using mass spectroscopy is critical. Urinary sediment analysis demonstrates glycolipid excretion of large quantities of globotriaosylceramide and galabiosylceramide in affected individuals (26). CSF is remarkable for the presence of large quantities of globotriaosylceramide (83). Skin biopsies will also show intralysosomal lipid deposition in clinically normal areas of skin (158).
Mutation analysis of the GLA gene. Molecular-based diagnostic testing can be performed quickly by using polymerase chain reaction amplification of exons followed by Sanger sequencing of each of the seven exons and adjacent intron boundaries (57). Intronic mutation with a complex haplotype is also associated with Fabry disease (117). Other molecular methods that have been utilized for identification of gene mutations and carrier detection include fluorescence-assisted mismatch analysis and linkage analysis using intragenic and closely linked polymorphisms (62; 27). There are many variants of the GLA gene, and many of them are mild or not associated with disease (141). Therefore, before concluding that a variant with relatively high α-galactosidase A activity is pathogenic, one must demonstrate evidence of altered sphingolipid homeostasis in a disease-relevant organ (141).
Neuroimaging. MRI studies have shown periventricular and other focal areas of signal intensity changes; these are thought to be clinically silent and associated with hyperperfusion (36; 103; 178; 125). The periventricular and other focal areas of signal intensity changes may resemble lesions in multiple sclerosis (125). Strokes are common; 23% of 71 patients in one series experienced a stroke (178). Calcifications of the pulvinar (posterior thalamus) on T1-weighted images are virtually diagnostic of Fabry disease (107). Proton MRS of the brain demonstrates a widespread reduction in N-acetylaspartate, suggesting diffuse neuronal involvement in Fabry disease (159).
-
White matter hyperintensities in the parietal-occipital lobes and basal ganglia in Fabry disease (MRI)
T2 FLAIR sequence shows white matter hyperintensities in the parietal-occipital lobes and basal ganglia in a patient with Fabry disease. (Source: Zhao Y, Zhu Y, Li F, et al. Brain MRI correlations with disease burden and biomar...
-
Multiple typical laterodorsal hyperintense lesions in the cervical spinal cord of a woman with Fabry disease (MRI)
Axial FLAIR of a 29-year-old woman with Fabry disease shows multiple typical laterodorsal hyperintense lesions in the cervical spinal cord. (Source: Rekova P, Kovarova I, Uher T, et al. Missed diagnosis of Fabry disease: should...
-
Discrete pathological MRI involvement in Fabry disease with a typical lesion distribution for multiple sclerosis
MRI of a 44-year-old woman with Fabry disease showing discrete pathological MRI involvement fulfilling MRI criteria with a typical lesion distribution for multiple sclerosis. Axial FLAIR shows small lesions in the frontal lobe ...
Neurophysiology. Although motor and sensory nerve conduction velocities are typically normal, the elevated thresholds demonstrated in a study for cold stimuli, and warm stimuli to a lesser extent, in several patients with Fabry disease suggest a small fiber neuropathy (95). Early diagnosis of peripheral neuropathy, especially of small nerve fiber involvement, in patients with suspected Fabry disease contributes not only to the diagnosis but also to the timely and effective initiation of Fabry disease therapy (86).
Other studies. Some cardiac abnormalities suggest Fabry disease: these include a short PR interval on EKG as well as low native T1 times and prolonged T2 relaxation times with multimodality cardiac imaging (161).
Increased carotid intima media thickness and decreased brachial flow-mediated dilation occur in classic Fabry disease, but the significance and usefulness of these findings have not been established (133).
Management
Symptomatic management
Symptomatic management was a constant in Fabry disease before the availability of enzyme replacement therapies. This was mostly directed toward the most distressing symptom for patients with Fabry disease, which is the painful peripheral neuropathy; carbamazepine, diphenylhydantoin, gabapentin, and lamotrigine alone or in combination frequently provide relief of this symptom (78; 148). Gabapentin may be preferred over carbamazepine because gabapentin has fewer side effects (129).
Despite the benefits of enzyme replacement therapy, particularly on the renal complications of the disease, it does not prevent vascular events such as stroke (04).
“Nonspecific” standard medical care is important and effective in Fabry disease. Ischemic stroke in Fabry disease should be prevented and treated in the same standard way as in the general population, including the use of effective antiplatelet agents such as clopidogrel, anticoagulants when atrial fibrillation is present, and intravenous thrombolysis (99; 81). For the prevention of ischemic strokes, aspirin/dipyridamole (Aggrenox®) or a platelet adenosine diphosphate chemoreceptor blocker (eg, clopidogrel) appear to be effective, whereas aspirin alone is not. These antiplatelet agents may be effective for both secondary and primary stroke prevention. Primary prevention should be initiated in the third decade of life in patients with Fabry disease with a family history of strokes, whether the strokes were clearly related or unrelated to Fabry disease. Other effective medical therapies include angiotensin receptor blockers and angiotensin II-converting enzyme inhibitors for proteinuria in renal disease, renal transplantation, and a variety of treatments for arrhythmia, cardiac insufficiency, and valve replacement (143).
Depression is a common problem in patients with Fabry disease, and it may be treated effectively with nonpharmacological interventions such as psychotherapy (02).
Renal transplantation corrects the renal failure in Fabry disease but does not provide enzymes to the rest of the body (150). An analysis of a case series of 197 kidney transplant recipients with Fabry disease found a superior graft survival and similar patient survival compared with patients with other causes of end-stage renal disease (151). However, patients with Fabry disease had a higher risk of death compared with a matched cohort of patients with other causes of end-stage renal disease. Caution should be used when considering a related donor transplant from a heterozygous female because many of these women also have asymptomatic but pathologically significant storage of glycolipids within the kidneys.
Cardiac transplantation alone or in conjunction with renal transplantation has been successfully performed in patients with Fabry disease (121).
Specific therapy
The only available primary specific therapies for Fabry disease are enzyme replacement therapy and pharmacological chaperone therapy.
Other treatment modalities under study include gene therapy, administration of exogenous mRNA via lipid nanoparticles, and substrate reduction therapy (60; 55).
It is likely that the efficacy of all specific therapies is significantly enhanced if treatment is initiated early in life, prior to the presence of irreversible changes in the kidney, heart, cerebral vasculature, and peripheral nerves (20; 122).
Enzyme replacement therapy. Because the accumulation of glycosphingolipid is the primary pathological feature seen in Fabry disease, several treatment approaches have been attempted either to provide the alpha-galactosidase A enzyme or secondarily to reduce the amount of accumulating glycosphingolipids.
Results of the initial treatment trials with enzyme replacement therapy provided evidence of substrate clearance in the endothelial cells of the kidneys, and from the vascular endothelium of the skin associated with clinical and quality of life improvements in the patients (52; 144) with an excellent safety profile. This led to regulatory approval in 2002 in Europe and in 2003 in the United States.
Studies using agalsidase alfa and agalsidase beta suggest that enzyme replacement therapy slows the progression of kidney disease (10; 138; 168). This therapy has only a small effect on cardiac disease (109).
Other pathologic aspects in Fabry disease, such as left ventricular hypertrophy, auditory impairment, and impaired cerebral blood flow, improve with enzyme replacement therapy (104). Improvements in peripheral nerve and sweat function, as well as cardiac improvement have been noted in treated patients (139; 167). However, strokes continue to occur on enzyme replacement therapy (171; 126; 145).
Enzyme replacement therapy can also be used in heterozygous females with Fabry disease (170).
Most studies that showed clinical improvements were open-label studies. Two meta-analyses showed little if any effect of enzyme replacement therapy in Fabry disease (49). However, a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference concluded that enzyme replacement therapy is the first specific therapy that has been developed that can slow kidney disease and alleviate symptoms, although it confers little benefit to cardiovascular and cerebrovascular outcomes (143).
Currently, approved enzyme replacement therapy has a short half-life. As a result, there is no residual therapeutic enzyme in the second week of the 2-week interval, thus, allowing progression of the disease (143). Another problem is the development of anti-alpha-galactosidase A antibodies, which reduce the activity and effectiveness of the infused enzyme (155).
To mitigate these problems, a novel modified enzyme (pegunigalsidase alfa) has been developed for Fabry disease (142) and has been approved in the European Union and United States for the treatment of Fabry disease (72). This product has a prolonged circulatory half-life (approximately 80 hours) compared with other currently available enzyme replacement therapies (2 or fewer hours) and seems to be significantly less immunogenic (72). Pegunigalsidase alfa has been well tolerated (72).
Pharmacological chaperones. These are small molecules that, in high doses, are competitive inhibitors but, in lower concentrations, promote the correct folding and intracellular transport of the enzyme. Migalastat (1-deoxygalactonojirmycin) has shown clinical efficacy in two studies and was approved by the Food and Drug Administration and the European Medicine Agency (63; 73). It is an oral drug with the advantage that, unlike enzyme replacement therapy, it is widely distributed throughout the body, it leads to a stable increase of the endogenous enzyme level, and it has an excellent safety record with no immune concerns. Long-term clinical effects need to be obtained to assess its full efficacy.
Substrate synthesis reduction. Reduction of substrate load was tested as an alternative therapeutic approach using N-butyldeoxynojirimycin, known to inhibit the first step in globotriaosylceramide synthesis (118). Novel inhibitors of ceramide glycosyltransferase show promise at least in a Fabry disease mouse model (98), and studies in patients are currently in progress. Although it is too early to tell how effective this approach will be in Fabry disease, based on its effectiveness in Gaucher disease, substrate synthesis reduction may work in Fabry disease, particularly in patients with residual enzyme activity.
Special considerations
Pregnancy
In pregnancies at risk for an affected fetus, enzyme analysis can be performed on chorionic villus tissue obtained at 8 weeks to 12 weeks gestation or on cultured amniocytes obtained by amniocentesis later in the second trimester. Molecular diagnostic studies can identify a fetus at risk in families with a known mutation but also in families whose specific GLA gene mutations have yet to be determined (27).
Women with Fabry disease experience an increased pain burden during pregnancies and an increased risk for preeclampsia, prematurity, and small-for-gestational-age neonates (67). Because of the increased frequency of high-risk pregnancies, neonatal outcomes are somewhat worse in Fabry disease than in the general public (67).
Anesthesia
The risk associated with the use of anesthesia is increased because of the medical problems associated with Fabry disease. Specifically, cardiac disease, hypertension, and autonomic nervous system dysfunction may complicate anesthesia (166).
Media
References
- 01
- Alfen F, Putscher E, Hecker M, Zettl UK, Hermann A, Lukas J. Abnormal pre-mRNA splicing in exonic Fabry disease-causing GLA mutations. Int J Mol Sci 2022;23(23):15261. PMID 36499585
- 02
- Ali N, Gillespie S, Laney D. Treatment of depression in adults with Fabry disease. JIMD Rep 2018;38:13-21. PMID 28417336
- 03
- Amodio F, Caiazza M, Monda E, et al. An overview of molecular mechanisms in Fabry Disease. Biomolecules 2022;12(10):1460. PMID 36291669
- 04
- Anderson LJ, Wyatt KM, Henley W, et al. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014;37(6):969-78. PMID 24831586
- 05
- Anderson W. A case of 'angeio-keratoma.' Br J Dermatol 1898;10:113-7.
- 06
- Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol 2017;28(5):1631-41. PMID 27979989
- 07
- Auray-Blais C, Blais CM, Ramaswami U, et al. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin Chim Acta 2015;438:195-204. PMID 25149322
- 08
- Auray-Blais C, Millington DS, Young SP, Clarke JT, Schiffmann R. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease. J Inherit Metab Dis 2009;32(2):303-8. PMID 19169844
- 09
- Baig S, Edward NC, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice. Europace 2018;20(F12):f153-61. PMID 29045633
- 10
- Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Int Med 2007;146(2):77-86. PMID 17179052
- 11
- Banks DE, Milutinovic J, Desnick RJ, et al. Silicon nephropathy mimicking Fabry's disease. Am J Nephrol 1983;3:279-84. PMID 6416069
- 12
- Bar N, Karaa A, Kiser K, Kuo B, Zar-Kessler C. Gastrointestinal sensory neuropathy and dysmotility in Fabry disease: presentations and effect on patient's quality of life. Clin Transl Gastroenterol 2023;14(12):e00633. PMID 37578052
- 13
- Bernstein HS, Bishop DF, Astrin KH, et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest 1989;83:1390-9. PMID 2539398
- 14
- Bishop DF, Calhoun DH, Bernstein HS, et al. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A 1986;83:4859-63. PMID 3014515
- 15
- Bishop DF, Kornreich R, Desnick RJ. Structural organization of the alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci U S A 1988;85:3903-7. PMID 2836863
- 16
- Bloomfield SE, David DS, Rubin AL. Eye findings in the diagnosis of Fabry's disease. Patients with renal failure. JAMA 1978;240:647-9. PMID 97403
- 17
- Boutin M, Menkovic I, Martineau T, Vaillancourt-Lavigueur V, Toupin A, Auray-Blais C. Separation and analysis of lactosylceramide, galabiosylceramide, and globotriaosylceramide by LC-MS/MS in urine of Fabry disease patients. Anal Chem 2017;89(24):13382-90. PMID 29099167
- 18
- Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-7. PMID 6023233
- 19
- Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal Disease: influence of alpha- galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81(2):122-38. PMID 11889412
- 20
- Braun F, Blomberg L, Brodesser S, et al. Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling. Cell Physiol Biochem 2019;52(5):1139-50. PMID 30990584
- 21
- Brown LK, Miller A, Bhuptani A, et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med 1997;155:1004-10. PMID 9116979
- 22
- Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 2011;11:61. PMID 21619592
- 23
- Burton BK, Charrow J, Hoganson GE, et al. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr 2017;190:130-5. PMID 28728811
- 24
- Cable WJ, Dvorak AM, Osage JE, Kolodny EH. Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves. Neurology 1982a;32:347-53. PMID 6278363
- 25
- Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology 1982b;32:498-502. PMID 6803189
- 26
- Cable WJ, McCluer RH, Kolodny EH, Ullman MD. Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 1982c;32:1139-45. PMID 6289188
- 27
- Caggana M, Ashley GA, Desnick RJ, Eng CM. Fabry disease: molecular carrier detection and prenatal diagnosis by analysis of closely linked polymorphisms at Xq22.1. Am J Med Genet 1997;71:329-35. PMID 9268104
- 28
- Carnicer-Caceres C, Arranz-Amo JA, Cea-Arestin C, et al. Biomarkers in Fabry disease: implications for clinical diagnosis and follow-up. J Clin Med 2021;10(8):1664. PMID 33924567
- 29
- Chien YH, Lee NC, Chiang SC, Desnick RJ, Hwu WL. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations. Mol Med 2012;18:780-4. PMID 22437327
- 30
- Chimenti C, Morgante E, Tanzilli G, et al. Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail 2008;1(3):161-9. PMID 19808286
- 31
- Chiramel AI, Brady NR, Bartenschlager R. Divergent roles of autophagy in virus infection. Cells 2013;2(1):83-104. PMID 24709646
- 32
- Cianci V, Pascarella A, Gasparini S, et al. Late-onset Fabry disease due to a new (p.Pro380Leu) pathogenic variant of GLA Gene. Metab Brain Dis 2022;37(8):3023-6. PMID 36178639
- 33
- Cianci V, Pascarella A, Manzo L, et al. Late-onset fabry disease due to the p.Phe113Leu variant: the first italian cluster of five families. Metab Brain Dis 2023;38(6):1905-12. PMID 37097439
- 34
- Coelho-Ribeiro B, Silva HG, Sampaio-Marques B, et al. Inflammation and exosomes in Fabry disease pathogenesis. Cells 2024;13(8):654. PMID 38667269
- 35
- Cross EG. The familial occurrence of erythromelalgia and nephritis. Can Med Assoc J 1962;87(1):1-4. PMID 13882378
- 36
- Crutchfield KE, Patronas NJ, Dambrosia DM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998;50:1746-9. PMID 9633721
- 37
- Davies JP, Winchester BG, Malcolm S. Sequence variations in the first exon of alpha-galactosidase A. J Med Genet 1993b;30:658-63. PMID 8411052
- 38
- DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000;47(2):229-33. PMID 10665494
- 39
- De Groot WP. Genetic aspects of the thesaurismosis lipoidica hereditaria Ruiter-Pompen-Wyers (angiokeratoma corporis diffusum Fabry). Dermatologica 1964;129:281-2. PMID 14241684
- 40
- Desnick RJ, Allen KY, Desnick SJ, et al. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973;81:157-71. PMID 4683418
- 41
- Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 1976;54:818-25. PMID 824066
- 42
- Desnick RJ, Eng CM. Fabry disease: alpha-galactosidase A deficiency. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, editors. The molecular and genetic basis of neurological disease. 2nd edition. Boston: Butterworth-Heinemann, 1997:443-52.
- 43
- Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 1995:2741-84.
- 44
- Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th edition. New York: McGraw-Hill, 2001:3733-74.
- 45
- deVeber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 1992;31:409-15. PMID 1375013
- 46
- Dobyns WB. The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. Acta Paediatr Suppl 2006;95(451):11-5. PMID 16720459
- 47
- Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017. J Med Genet 2018;55(4):261-8. PMID 29330335
- 48
- Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016;89(1):44-54. PMID 25974833
- 49
- El Dib R, Gomaa H, Carvalho RP, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2016;7:CD006663. PMID 27454104
- 50
- Eng CM, Ashley GA, Burgert TS, et al. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997;3:174-82. PMID 9100224
- 51
- Eng CM, Desnick DJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat 1994;3:103-11. PMID 7911050
- 52
- Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A- replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16. PMID 11439963
- 53
- Eng CM, Niehaus DJ, Enriquez AL, et al. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet 1994;3:1795-9. PMID 7531540
- 54
- Ersoz MG, Ture G. Cilioretinal artery occlusion and anterior ischemic optic neuropathy as the initial presentation in a child female carrier of Fabry disease. Int Ophthalmol 2018;38(2):771-3. PMID 28281207
- 55
- Ezgu F, Alpsoy E, Bicik Bahcebasi Z, et al. Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective. Orphanet J Rare Dis 2022;17(1):90. PMID 35236382
- 56
- Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)" [A contribution to the knowledge of the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Archiv für Dermatologie und Syphilis 1898;43(1):187-200.
- 57
- Feldt-Rasmussen U, Dobrovolny R, Nazarenko I, et al. Diagnostic dilemma: a young woman with Fabry disease symptoms, no family history, and a "sequencing cryptic" alpha-galactosidase a large deletion. Mol Genet Metab 2011;104(3):314-8. PMID 21641253
- 58
- Fellgiebel A, Keller I, Martus P, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 2011;31(3):294-9. PMID 21196729
- 59
- Font RL, Fine BS. Ocular pathology in Fabry's disease. Histochemical and electron microscopic observations. Am J Ophthalmol 1972;73:419-30. PMID 4335185
- 60
- Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345(1):25-32. PMID 11439944
- 61
- Gaggl M, El-Hadi S, Aigner C, Sunder-Plassmann G. The renal history of Fabry disease. G Ital Nefrol 2016;33 Suppl 66:33.S66.14. PMID 26913882
- 62
- Germain D, Biasotto M, Tosi M, Meo T, Kahn A, Poenaru L. Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease. Hum Genet 1996;98:719-26. PMID 8931708
- 63
- Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med 2016;375(6):545-55. PMID 27509102
- 64
- Giuseppe P, Daniele R, Rita BM. Cutaneous complications of Anderson-Fabry disease. Curr Pharm Des 2013;19(33):6031-6. PMID 23448454
- 65
- Glass RB, Astrin KH, Norton KI, et al. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr 2004;28(2):158-68. PMID 15091117
- 66
- Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005;84(5):261-8. PMID 16148726
- 67
- Haninger-Vacariu N, Anastopoulos K, Aigner C, et al. Pregnancy outcomes of Fabry disease in Austria (PROFABIA)-a retrospective cohort-study. Orphanet J Rare Dis 2024;19(1):165. PMID 38637893
- 68
- Heywood WE, Doykov I, Spiewak J, Hallqvist J, Mills K, Nowak A. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients. Biochim Biophys Acta Mol Basis Dis 2019;1865(10):2726-35. PMID 31319156
- 69
- Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 2000;84(2-3):361-5. PMID 10666542
- 70
- Hossain MA, Wu C, Yanagisawa H, Miyajima T, Akiyama K, Eto Y. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLA gene. Mol Genet Metab Rep 2019;20:100497. PMID 31372342
- 71
- Hossain MA, Yanagisawa H, Miyajima T, et al. The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome. Mol Genet Metab 2017;120(3):173-9. PMID 28087245
- 72
- Hughes D, Gonzalez D, Maegawa G, et al. Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult patients with Fabry disease. Genet Med 2023;25(12):100968. PMID 37634127
- 73
- Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017;54(4):288-96. PMID 27834756
- 74
- Hurwitz S. Clinical pediatric dermatology: a textbook of skin disorders in childhood and adolescence. Philadelphia: WB Saunders, 1993:242-77.
- 75
- Inagaki S, Migita M, Hayakawa M, et al. An asymptomatic heterozygous female with fabry disease: implications for enzyme replacement therapy. J Nippon Med Sch 2005;72(6):387-90. PMID 16415520
- 76
- Inagaki M, Ohno K, Ohta S, Sakuraba H, Takeshita K. Relief of chronic burning pain in Fabry disease with neurotropin. Pediatr Neurol 1990;6:211-3. PMID 2113806
- 77
- Izhar R, Borriello M, La Russa A, et al. fabry disease in women: genetic basis, available biomarkers, and clinical manifestations. Genes (Basel) 2023;15(1):37. PMID 38254927
- 78
- Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002;6(Suppl A):61-8. PMID 11888243
- 79
- Jovanovic A, Miller-Hodges E, Castriota F, Takyar S, Howitt H, Ayodele O. A systematic literature review on the health-related quality of life and economic burden of Fabry disease. Orphanet J Rare Dis 2024;19(1):181. PMID 38689282
- 80
- Juang JJ, Shun CT, Chen YS, et al. Fabry disease cardiac variant IVS4+919 G>A is associated with multiple cardiac gene variants in patients with severe cardiomyopathy and fatal arrhythmia. Gen Med 2019;21(8):1890-1. PMID 30662066
- 81
- Kargiotis O, Psychogios K, Safouris A, et al. Intravenous thrombolysis for acute ischemic stroke in Fabry disease. Neurologist 2019;24(5):146-9. PMID 31478997
- 82
- Kaye EM, Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23:505-9. PMID 3133979
- 83
- Kaye EM, Ullman MD, Kolodny EH, Krivit W, Rischert JC. Possible use of CSF glycosphingolipids for the diagnosis and therapeutic monitoring of lysosomal storage diseases. Neurology 1992;42:2290-4. PMID 1461381
- 84
- Kikumoto Y, Kai Y, Morinaga H, et al. Fabry disease exhibiting recurrent stroke and persistent inflammation. Intern Med 2010;49(20):2247-52. PMID 20962444
- 85
- Kirkilionis AJ, Riddell DC, Spence MW, Fenwick RG. Fabry disease in a large Nova Scotia kindred: carrier detection using leucocyte alpha-galactosidase activity and an NcoI polymorphism detected by an alpha-galactosidase cDNA clone. J Med Genet 1991;28(4):232-40. PMID 1677424
- 86
- Kokotis P, Zompola C, Anastasakis A, et al. Clinical significance of small nerve fiber involvement in the early diagnosis and treatment of patients with Fabry disease. J Neurol Sci 2023;453:120776. PMID 37797349
- 87
- Kono Y, Wakabayashi T, Kobayashi M, et al. Characteristics of cerebral microbleeds in patients with Fabry disease. J Stroke Cerebrovasc Dis 2016;25(6):1320-5. PMID 26987491
- 88
- Kornreich R, Bishop DF, Desnick RJ. Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene. J Biol Chem 1990;265:9319-26. PMID 2160973
- 89
- Kornreich R, Desnick RJ, Bishop DF. Nucleotide sequence of human alpha-galactosidase A gene. Nucleic Acids Res 1989;17:3301-2. PMID 2542896
- 90
- Lelieveld IM, Bottcher A, Hennermann JB, Beck M, Fellgiebel A. Eight-year follow-up of neuropsychiatric symptoms and brain structural changes in Fabry disease. PloS One 2015;10(9).e0137603. PMID 26340726
- 91
- Linares D, Luna B, Loayza E, Taboada G, Ramaswami U. Prevalence of Fabry disease in patients with chronic kidney disease: a systematic review and meta-analysis. Mol Genet Metab 2023;140(4):107714. PMID 37918171
- 92
- Linthorst GE, Folman CC, Aerts JM, Hollak CE. Blood group does not correlate with disease severity in patients with Fabry disease (alpha-galactosidase A deficiency). Blood Cells Mol Dis 2003;31(3):324-6. PMID 14636646
- 93
- Lou HO. Genetic, biochemical and clinical investigations in angiokeratoma corporis diffusum (Fabry's disease). Acta Neurol Scand 1970;46(S43):256-8. PMID 5457845
- 94
- Lu Z, Huang G, Yu L, et al. Low skeletal muscle mass as an early sign in children with fabry disease. Orphanet J Rare Dis 2023;18(1):199. PMID 37480128
- 95
- Luciano CA, Russell JW, Banerjee T, et al. Physiologic characterization of neuropathy in Fabry disease. Muscle Nerve 2002;26(5):622-9. PMID 12402283
- 96
- MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001;429(1-3):121-5. PMID 11698033
- 97
- Marchesoni C, Cisneros E, Pfister P, et al. Brain MRI findings in children and adolescents with Fabry disease. J Neurol Sci 2018;395:131-4. PMID 30316069
- 98
- Marshall J, Ashe KM, Bangari D, et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PloS One 2010;5(11):e15033. PMID 21124789
- 99
- Mehta A, West ML, Pintos-Morell G, et al. Therapeutic goals in the treatment of Fabry disease. Genet Med 2010;12(11):713-20. PMID 20975569
- 100
- Meng XL, Arning E, Wight-Carter M, et al. Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expression. J Inherit Metab Dis 2018;41(2):231-8. PMID 29110178
- 101
- Miyamura N, Araki E, Matsuda K, et al. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. J Clin Invest 1996;98:1809-17. PMID 8878432
- 102
- Monda E, Diana G, Graziani F, et al. Impact of GLA variant classification on the estimated prevalence of Fabry disease: a systematic review and meta-analysis of screening studies. Circ Genom Precis Med 2023;16(6):e004252. PMID 38047356
- 103
- Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003a;62(3):231-40. PMID 14698356
- 104
- Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002;2:4. PMID 12079501
- 105
- Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104(13):1506-12. PMID 11571244
- 106
- Moore DF, Ye F, Brennan ML, et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 2004;20(4):674-83. PMID 15390234
- 107
- Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 2003b;24(6):1096-101. PMID 12812932
- 108
- Najafian B, Fogo AB, Lusco MA, Alpers CE. AJKD atlas of renal pathology: Fabry nephropathy. Am J Kidney Dis 2015;66(5):e35-6. PMID 26498420
- 109
- Nordin S, Kozor R, Vijapurapu R, et al. Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging 2019;12(12):e009430. PMID 31826677
- 110
- O'Brien JS, Kretz KA, Dewji N, et al. Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science 1988;241:1098-101. PMID 2842863
- 111
- Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol 1974;31:120-7. PMID 4135101
- 112
- Opitz JM, Stiles FC, Wise D, et al. The genetics of angiokeratoma corporis diffusum (Fabry's disease) and its linkage relations with the Xg locus. Am J Hum Genet 1965;17(4):325-42.** PMID 17948499
- 113
- Palaiodimou L, Papagiannopoulou G, Bakola E, et al. Impaired cerebral autoregulation in Fabry disease: a case-control study. J Neuroimaging 2023;33(4):582-9. PMID 37147184
- 114
- Palecek T, Honzikova J, Poupetova H, et al. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis 2014;37(3):455-60. PMID 24173410
- 115
- Penix L, Lanska DJ. Cerebrovascular disease. In: Mattson M, editor. Genetic aberrancies and neurodegenerative disorders. Advances in cell aging and gerontology. Volume 3. Greenwich: JAI Press, 1999:243-86.
- 116
- Phyu P, Merwick A, Davagnanam I, et al. Increased resting cerebral blood flow in adult Fabry disease: MRI arterial spin labeling study. Neurology 2018;90(16):e1379-e85. PMID 29661900
- 117
- Pisani A, Imbriaco M, Zizzo C, et al. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. BMC Cardiovasc Disord 2012;12(1):39. PMID 22682330
- 118
- Platt FM, Neises GR, Dwek RA, Butter TD. N-butylnojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994;269:8362-5. PMID 8132559
- 119
- Pompen AW, Ruiter M, Wyers JH. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease: two autopsy reports. Acta Med Scand 1947;128:234-55. PMID 18897399
- 120
- Rahman AN, Lindenberg R. The neuropathology of hereditary dystopic lipidosis. Arch Neurol 1963;9:373-85. PMID 14060085
- 121
- Rajagopalan N, Dennis DR, O'Connor W. Successful combined heart and kidney transplantation in patient with Fabry's disease: a case report. Transplant Proc 2019;51(9):3171-3. PMID 31371217
- 122
- Ramaswami U, Bichet DG, Clarke LA, et al. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: a 5-year randomized controlled trial. Mol Genet Metab 2019;127(1):86-94. PMID 30987917
- 123
- Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, et al. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 1996;33:682-8. PMID 8863162
- 124
- Rekova P, Dostalova G, Rob D, et al. Cerebrovascular phenotype in Fabry disease patients assessed by ultrasound. J Ultrasound Med 2023;42(10):2315-30. PMID 37209359
- 125
- Rekova P, Kovarova I, Uher T, et al. Missed diagnosis of Fabry disease: should we screen patients with multiple sclerosis? Neurol Sci 2024;45(1):231-9. PMID 37480392
- 126
- Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118(3):924-32. PMID 16950982
- 127
- Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Pediatrics 2005;115:e344-55. PMID 15713906
- 128
- Ries M, Kim HJ, Zalewski CK, et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 2007;130(Pt 1):143-50. PMID 17105746
- 129
- Ries M, Mengel E, Kutschke G, et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. Journal of inherited metabolic disease 2003;26(4):413-4. PMID 12971431
- 130
- Rocchetti MT, Spadaccino F, Catalano V, et al. Metabolic fingerprinting of Fabry disease: diagnostic and prognostic aspects. Metabolites 2022;12(8):703. PMID 36005574
- 131
- Rolfs A, Fazekas F, Grittner U, et al. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke 2013;44(2):340-9. PMID 23306324
- 132
- Romani I, Sarti C, Nencini P, et al. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: the challenge to widen the screening. The Fabry-Stroke Italian Registry. J Neurol Sci 2024;457:122905. PMID 38295534
- 133
- Rombach SM, van den Bogaard B, de Groot E, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 2012;60(4):998-1005. PMID 22868390
- 134
- Sahyoun JY, Sabeti S, Robert MC. Drug-induced corneal deposits: an up-to-date review. BMJ Open Ophthalmol 2022;7(1):e000943. PMID 35415268
- 135
- Sanchez R, Ripoll-Vera T, López-Mendoza M, et al. The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants. Orphanet J Rare Dis 2023;18(1):8. PMID 36624527
- 136
- Savostyanov K, Pushkov A, Zhanin I, et al. Genotype-phenotype correlations in 293 Russian patients with causal Fabry disease variants. Genes (Basel) 2023;14(11):2016. PMID 38002959
- 137
- Sawada T, Kido J, Yoshida S, et al. Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep 2020;22:100562. PMID 31956509
- 138
- Schiffmann R. Fabry disease. Pharmacol Ther 2009;122(1):65-77. PMID 19318041
- 139
- Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28(6):703-10. PMID 14639584
- 140
- Schiffmann R, Forni S, Swift C, et al. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. J Am Heart Assoc 2014;3(1):e000394. PMID 24496231
- 141
- Schiffmann R, Fuller M, Clarke LA, Aerts JM. Is it Fabry disease? Genet Med 2016;18(12):1181-5. PMID 27195818
- 142
- Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1/2 clinical trial. J Inherit Metab Dis 2019;42(3):534-44. PMID 30834538
- 143
- Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis and management of patients with Fabry disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017a;91(2):284-93. PMID 27998644
- 144
- Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9. PMID 11386930
- 145
- Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21(2):345-54. PMID 16204287
- 146
- Schiffmann R, Swift C, McNeill N, et al. Low frequency of Fabry disease in patients with common heart disease. Genet Med 2018;20(7):754-9. PMID 29227985
- 147
- Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009;24(7):2102-11. PMID 19218538
- 148
- Schuller Y, Linthorst GE, Hollak CE, Van Schaik IN, Biegstraaten M. Pain management strategies for neuropathic pain in Fabry disease--a systematic review. BMC Neurol 2016;16:25. PMID 26911544
- 149
- Scott LJ, Griffin JW, Luciano C, et al. Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999;52(6):1249-54. PMID 10214752
- 150
- Sessa A, Meroni M, Battini G, Righetti M, Mignani R. Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease. Sem Nephrol 2004;24(5):532-6. PMID 15490423
- 151
- Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S. Kidney transplant outcomes in patients with Fabry disease. Transplantation 2009;87(2):280-5. PMID 19155985
- 152
- Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009;40(3):788-94. PMID 19150871
- 153
- Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet 2015;52(4):262-8. PMID 25596309
- 154
- Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79(1):31-40. PMID 16773563
- 155
- Stappers F, Scharnetzki D, Schmitz B, et al. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity. J Inherit Metab Dis 2020;43(2):334-7. PMID 31587315
- 156
- Stefaniak JD, Parkes LM, Parry-Jones AR, et al. Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease. Neurology 2018;91(15):e1413-22. PMID 30209238
- 157
- Sweeley CC, Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963;238:3148-50. PMID 14081947
- 158
- Tarnowski WM, Hashimoto K. New light microscopic skin findings in Fabry's disease. Study of four patients using plastic-embedded tissue. Acta Derm Venereol 1969;49:386-9. PMID 4185107
- 159
- Tedeschi G, Bonavita S, Banerjee TK, Virta A, Schiffmann R. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 1999;52:1663-7. PMID 10331696
- 160
- Tomar OK, Bal AZ, Şirali SK, et al. The prevalence of Fabry disease in a Turkish population with chronic kidney patients. Int Urol Nephrol 2023;55(6):1629-34. PMID 36725792
- 161
- Tower-Rader A, Jaber WA. Multimodality imaging assessment of Fabry disease. Circ Cardiovasc Imaging 2019;12(11):e009013. PMID 31718277
- 162
- Uceyler N, Homola GA, Guerrero Gonzalez H, et al. Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. PloS One 2014;9(1):e87054. PMID 24475221
- 163
- Valtola K, Hedman M, Kantola I, et al. Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation. Open Heart 2023;10(1):e002251. PMID 36927868
- 164
- Vetrie D, Kendall E, Coffey A, et al. A 6.5 yeast artificial chromosome contig incorporating 33 DNA markers on the human X chromosome at Xq22. Genomics 1994;19:42-7. PMID 8188239
- 165
- Wanner C, Feldt-Rasmussen U, Jovanovic A, et al. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. ESC Heart Fail 2020;7(3):825-34. PMID 32100468
- 166
- Watanabe H, Aoki T, Ono A. The anesthetic management of a patient with Fabry's disease. Masui 1995;44:1258-60. PMID 8523662
- 167
- Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108(11):1299-301. PMID 12952834
- 168
- West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20(5):1132-9. PMID 19357250
- 169
- Whitley CB, Tsai MY, Heger JJ, Prystowsky EN, Zipes DP. Amiodarone phenocopy of Fabry's keratopathy. JAMA 1983;249:2177-8. PMID 6300478
- 170
- Whybra C, Miebach E, Mengel E, et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 2009;11(6):441-9. PMID 19346951
- 171
- Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75(1):65-74. PMID 15154115
- 172
- Winter Y, Hilz M, Beuschlein F, et al. Screening for health-related quality of life and its determinants in Fabry disease: a cross-sectional multicenter study. Mol Genet Metab 2023;140(3):107692. PMID 37703724
- 173
- Wu Y, Zhang W, Yao X, et al. Investigation of ocular involvement in patients with Fabry disease. Ann Med 2023;55(1):2226909. PMID 37354009
- 174
- Yanfang W, Juanjuan H, Shengli Z, Lei Y, Fei G. Case report and literature review: Fabry disease misdiagnosing as polymyalgia rheumatica. Medicine (Baltimore) 2023;102(44):e34630. PMID 37933054
- 175
- Wise D, Wallace HJ, Jellinek EH. Angiokeratoma corporis diffusum. A clinical study of eight affected families. Q J Med 1962 Apr;31:177-206. PMID 14007664
- 176
- Yang TH, Xirasagar S, Cheng YF, Chen CS, Lin HC. Increased prevalence of peripheral vestibular disorder among patients with Fabry disease. Orphanet J Rare Dis 2024;19(1):97. PMID 38431642
- 177
- Yenercag M, Arslan U. Tp-e interval and Tp-e/QT ratio and their association with left ventricular diastolic dysfunction in Fabry disease without left ventricular hypertrophy. J Electrocardiol 2019;59:20-4. PMID 31945689
- 178
- Zhao Y, Zhu Y, Li F, et al. Brain MRI correlations with disease burden and biomarkers in Fabry disease. J Neurol 2023;270(10):4939-48. PMID 37356023
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Former Authors
- Edward M Kaye MD
- Mario A Cabrera-Salazar MD
- John A Barranger MD PhD
- Raphael Schiffmann MD
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- male>female, >2:1
- Heredity
-
- heredity typical
- heredity may be a factor
- sex-linked recessive
- Population groups selectively affected
-
- Caucasians
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-9
-
- Fabry disease: 272.7
- ICD-10
-
- Fabry disease: E75.2
- OMIM
-
- Fabry disease: #301500
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Sleep Disorders
Fatal familial insomnia
Sep. 25, 2024
-
Neurogenetic Disorders
Hypermethioninemia
Sep. 12, 2024
-
Neurogenetic Disorders
Multiple acyl-CoA dehydrogenase deficiency
Sep. 12, 2024
-
Neurogenetic Disorders
Medium-chain acyl-CoA dehydrogenase deficiency
Sep. 12, 2024
-
Neurogenetic Disorders
Long-chain fatty acid oxidation defects
Sep. 12, 2024
-
General Neurology
Hyperventilation syndrome
Sep. 03, 2024
-
Neurogenetic Disorders
Nonketotic hyperglycinemia
Sep. 03, 2024